natgillin/translations-raw huggingface dataset:
There was a higher incidence of grade 3/4 ADRs in patients with bulky disease than in patients without bulky disease (25.6% vs. 15.4%).
Bolniki z obsežno boleznijo so imeli višjo incidenco neželenih učinkov 3. ali 4. stopnje kot bolniki brez obsežne bolezni (25,6% v primerjavi s 15,4%).
Significant benefit from maintenance treatment with rituximab was also seen for the secondary endpoints event-free survival (EFS), time to next anti-lymphoma treatment (TNLT) time to next chemotherapy (TNCT) and overall response rate (ORR) in the primary analysis (Table 7).
Pomembna korist vzdrževalnega zdravljenja z rituksimabom se je pokazala tudi pri sekundarnih opazovanih dogodkih - preživetju brez dogodkov (event-free survival - EFS), času do naslednjega zdravljenja limfoma (time to next anti-lymphoma treatment - TNLT), času do naslednje kemoterapije (time to next chemotherapy - TNCT) in celokupnem odgovoru (overall response rate - ORR) v primarni analizi (preglednica 7).
Rituximab infusions were administered after an intravenous infusion of 100 mg methylprednisolone; patients also received treatment with oral prednisone for 15 days.
Infuzija rituksimaba je sledila intravenski infuziji 100 mg metilprednizolona; bolniki so 15 dni tudi peroralno jemali prednizon.
The median duration of response was 37.7 months in the R-CVP group and was 13.5 months in the CVP group (p < 0.0001, log-rank test).
Mediano trajanje odgovora je bilo 37,7 meseca v skupini z R-CVP in 13,5 meseca v skupini s CVP (p < 0,0001, log-rang test).
In addition, other serious viral infections either new, reactivated or exacerbated, some of which were fatal, have been reported with rituximab treatment.
Poleg tega so med zdravljenjem z rituksimabom opisane druge resne virusne okužbe, bodisi novonastale, ponovitve ali poslabšanja; nekatere so bile smrtne.
What Ritemvia looks like and contents of the pack
Izgled zdravila Ritemvia in vsebina pakiranja
6 observed mainly in patients with prior cardiac condition and/or cardiotoxic chemotherapy and were mostly associated with infusion-related reactions
6 Opaženi v glavnem pri bolnikih z obstoječimi boleznimi srca in/ali kardiotoksično kemoterapijo ter pretežno v zvezi z reakcijami, povezanimi z infuzijo.
Patients in the rituximab group who relapsed could receive an additional infusion of rituximab 1000 mg in combination with reintroduced or escalated prednisone dose.
Bolniki v skupini z rituksimab, ki se jim je pojavil recidiv, so lahko prejeli dodatno infuzijo 1.000 mg rituksimab v kombinaciji s ponovno uvedenim prednizonom ali povečanjem odmerka prednizona.
This is a disease of the lymph tissue (part of the immune system) that affects a type of white blood cell called B-Lymphocytes.
Ne-Hodgkinov limfom je bolezen limfatičnega tkiva (ta je del imunskega sistema), ki prizadene vrsto belih krvnih celic, limfocite B.
In clinical trials more than 3100 patients received at least one treatment course and were followed for periods ranging from 6 months to over 5 years; approximately 2400 patients received two or more courses of treatment with over 1000 having received 5 or more courses.
V kliničnih preskušanjih je več kot 3100 bolnikov prejelo najmanj en cikel zdravljenja, po tem so jih spremljali od 6 mesecev do več kot 5 let; približno 2.400 bolnikov je prejelo dva ali več ciklov zdravljenja, od teh pa več kot 1000 bolnikov 5 ali več ciklov zdravljenja.
• lower immunity - because of lower levels of anti-bodies called “immunoglobulins” (IgG)
zmanjšana imunost - zaradi manjše koncentracije protiteles, imenovanih imunoglobulini
Efficacy in autoantibody (RF and or anti-CCP) seropositive patients Patients seropositive to Rheumatoid Factor (RF) and/or anti-Cyclic Citrullinated Peptide (antiCCP) who were treated with rituximab in combination with methotrexate showed an enhanced response compared to patients negative to both.
Bolniki, serološko pozitivni za revmatoidni faktor (RF) in/ali anti-ciklični citrulinirani peptid (anti-CCP), ki so prejemali rituksimab v kombinaciji z metotreksatom, so imeli izrazitejši odziv kot bolniki, negativni za oba.
Based on the mechanism of action of rituximab and the knowledge that B cells play an important role in maintaining normal immune response, patients have an increased risk of infection following rituximab therapy (see section 5.1).
Glede na mehanizem delovanja zdravila rituksimab in dejstvo, da imajo celice B pomembno vlogo pri vzdrževanju normalnega imunskega odziva, imajo lahko bolniki, ki se zdravijo z zdravilom rituksimab, povečano tveganje za okužbe (glejte poglavje 5.1).
The incidence of ADRs of all grades and grade 3/4 ADR was similar in elderly patients compared to younger patients (< 65 years).
Incidenca neželenih učinkov vseh stopenj ter učinkov 3. ali 4. stopnje je bila pri starejših bolnikih podobna kot pri mlajših (< 65 let).
Table 6 Summary of key results from four phase III randomised studies evaluating the benefit of rituximab with different chemotherapy regimens in follicular lymphoma
Povzetek ključnih rezultatov štirih randomiziranih preskušanj III. faze, ki so ocenjevala korist rituksimaba v kombinaciji z različnimi shemami kemoterapije pri folikularnih limfomih
Patients should be closely monitored for the onset of cytokine release syndrome (see section 4.4).
Bolnike moramo zaradi možnosti pojava sindroma sproščanja citokinov (glejte poglavje 4.4) natančno opazovati.
When Ritemvia is given in combination with chemotherapy, standard dose reductions for the chemotherapeutic medicinal products should be applied.
Če zdravilo Ritemvia uporabimo v kombinaciji s kemoterapijo, je treba uporabiti standardno zmanjšanje odmerkov citostatikov.
However, dose-dependent pharmacologic depletion of B cells in the lymphoid organs of the foetuses was observed, which persisted post natally and was accompanied by a decrease in IgG level in the newborn animals affected.
Opazili pa so od odmerka odvisen farmakološki upad števila celic B v limfatičnih organih ploda, ki je trajal tudi postnatalno, spremljalo ga je tudi znižanje IgG pri pri prizadetih mladičih.
4.06 years
4,06 let
What Ritemvia is and what it is used for What Ritemvia is
Kaj je zdravilo Ritemvia in za kaj ga uporabljamo Kaj je zdravilo Ritemvia
The pharmacokinetic profile of rituximab when administered as 6 infusions of 375 mg/m2 in combination with 6 cycles of CHOP chemotherapy was similar to that seen with rituximab alone.
Farmakokinetični profil rituksimaba, dajanega v 6 infuzijah po 375 mg/m2 v kombinaciji s šestimi cikli kemoterapije CHOP, je bil podoben kot pri dajanju samega rituksimaba.
Medicines given before each Ritemvia administration
Zdravila, ki jih boste dobili pred vsakim dajanjem zdravila Ritemvia
The acute respiratory failure may be accompanied by events such as pulmonary interstitial infiltration or oedema, visible on a chest X-ray.
Akutno odpoved dihal lahko spremljajo spremembe, kot je infiltracija pljučnega intersticija ali pljučni edem, vidne na rentgenogramu prsnih organov.
Significant difference from placebo + MTX at the primary time point: ***p ≤ 0.0001
Značilna razlika v primerjavi s kombinacijo placebo + metotreksat ob času primarnega cilja preskušanja: ***p ≤ 0,0001
Symptoms of infusion-related reactions were similar in type and severity to those seen in RA and GPA/MPA patients.
Simptomi z infundiranjem povezanih reakcij so bili po vrsti in izrazitosti podobni simptomom, opaženim pri bolnikih z RA in GPA/MPA.
1 includes reactivation and primary infections; frequency based on R-FC regimen in relapsed/refractory CLL 2 see also section infection below
1 Vključuje reaktivacijo in primarne okužbe; pogostnost temelji na režimu R-FC pri bolnikih s KLL, pri katerih se je bolezen ponovila, ali pri neodzivnih bolnikih.
Medicinal products for the treatment of hypersensitivity reactions, e.g. epinephrine (adrenaline), antihistamines and glucocorticoids, should be available for immediate use in the event of an allergic reaction during administration of rituximab.
Zdravila za zdravljenje reakcij preobčutljivosti, npr. adrenalin, antihistaminiki in glukokortikoidi, morajo biti na voljo za takojšnjo uporabo, če bi se med dajanjem zdravila rituksimab pojavile alergijske reakcije.
Rituximab was administered on the first day of each treatment cycle.
Rituksimab je bil uporabljen prvi dan vsakega cikla zdravljenja.
Cases of grade 3 or 4 arrhythmia (including ventricular and supraventricular tachycardia) and angina pectoris during infusion were reported.
Med infuzijo sta se pojavili tudi aritmija 3. ali 4. stopnje (vključno z ventrikularno in supraventrikularno tahikardijo) in angina pektoris.
If any doubt exists, further evaluation, including MRI scan preferably with contrast, cerebrospinal fluid (CSF) testing for JC Viral DNA and repeat neurological assessments, should be considered.
V primeru dvoma je smiselno nadaljnje ovrednotenje, vključno z magnetnoresonančno preiskavo (MR), po možnosti s kontrastom, določanjem prisotnosti DNK virusa JC v cerebrospinalni tekočini in ponovno nevrološko oceno.
Structural joint damage was assessed radiographically and expressed as change in modified Total Sharp Score (mTSS) and its components, the erosion score and joint space narrowing score.
Strukturno okvaro sklepov so ocenili radiološko in jo izrazili kot spremembo ocene po prirejeni Sharpovi lestvici (mTSS, modified Total Sharp Score) in njenih komponent, ocene erozij in ocene zožitve sklepne špranje.
Rituximab +MTX 2 × 1000 mg
Rituksimab + metotreksat 2 × 1.000 mg
Rituximab+MTX (2 x 1000 mg)
Rituksimab + metotreksat (2 x 1.000 mg)
If you are being treated for granulomatosis with polyangiitis, microscopic polyangiitis or pemphigus vulgaris, you will also find this information in the Patient Alert Card you have been given by your doctor.
Če se zdravite zaradi granulomatoze s poliangiitisom, mikroskopskega poliangiitisa ali navadnega pemfigusa, boste te podatke našli tudi na opozorilni kartici za bolnika, ki vam jo je dal vaš zdravnik.
Biotec House, Central Park, Western Avenue Bridgend Industrial Estate Bridgend, CF31 3RT, UK
Biotec House, Central Park, Western Avenue Bridgend Industrial Estate Bridgend, CF31 3RT, Velika Britanija
In the maintenance therapy clinical trial, no clinically meaningful differences between the two treatment arms or decreases in total immunoglobulin, IgG, IgM or IgA levels were observed throughout the trial.
V kliničnem preskušanju vzdrževalnega zdravljenja med celotnim preskušanjem niso ugotovili pomembnih razlik med obema terapevtskima skupinama ali znižanja koncentracije celokupnih imunoglobulinov, IgG, IgM ali IgA.
For intravenous use after dilution.
Za intravensko uporabo po razredčitvi.
• If you are having Ritemvia with chemotherapy Ritemvia will be given to you on the same day as your chemotherapy.
Če prejemate zdravilo Ritemvia skupaj s kemoterapijo, ga boste dobili isti dan kot kemoterapijo.
In patients with granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis, methylprednisolone given intravenously for 1 to 3 days at a dose of 1000 mg per day is recommended prior to the first infusion of Ritemvia (the last dose of methylprednisolone may be given on the same day as the first infusion of Ritemvia).
Pri bolnikih z granulomatozo s poliangiitisom (Wegenerjevo granulomatozo) ali mikroskopskim poliangiitisom je pred prvo infuzijo zdravila Ritemvia priporočljiva intravenska uporaba metilprednizolona, ki se ga daje od 1 do 3 dni v odmerku 1000 mg na dan (zadnji odmerek metilprednizolona je lahko uporabljen na dan prve infuzije zdravila Ritemvia).
Patients with active hepatitis B disease should not be treated with rituximab.
Bolniki z aktivno boleznijo, ki jo povzroči virus hepatitisa B, se ne smejo zdraviti z zdravilom rituksimab.
Ritemvia maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy.
Vzdrževalno zdravljenje z zdravilom Ritemvia je indicirano za zdravljenje bolnikov s folikularnimi limfomi, ki se odzovejo na indukcijsko zdravljenje.
Patients were stratified by baseline disease severity (moderate or severe) and randomised 1:1 to receive either rituximab and low-dose prednisone or standard-dose prednisone.
Bolnike so stratificirali glede na izhodiščno izrazitost bolezni (zmerno ali hudo) in jih v razmerju 1:1 randomizirali ali na prejemanje zdravila rituksimab in majhnega odmerka prednizona ali na prejemanje standardnega odmerka prednizona.
Rituximab maintenance treatment provided consistent benefit in all predefined subgroups tested: gender (male, female), age (< 60 years, ≥ 60 years), FLIPI score (≤1, 2 or ≥ 3), induction therapy (RCHOP, R-CVP or R-FCM) and regardless of the quality of response to induction treatment (CR, CRu or PR).
Vzdrževalno zdravljenje z rituksimabom je pokazalo konsistentno korist pri vseh preiskovanih, vnaprej opredeljenih podskupinah glede na spol (moški, ženski), starost (< 60 let, ≥ 60 let), oceno po indeksu FLIPI (Follicular Lymphoma International Prognostic Index) (≤ 1, 2 ali ≥ 3), indukcijsko zdravljenje (R-CHOP, R-CVP ali R-FCM) in ne glede na odgovor na indukcijsko zdravljenje (CR/CRu ali PR).
A total of 810 patients (403 R-FC, 407 FC) for the first-line study (Table 10a and Table 10b) and 552 patients (276 R-FC, 276 FC) for the relapsed/refractory study (Table 11) were analysed for efficacy.
V analizo učinkovitosti je bilo vključenih skupno 810 bolnikov (403 R-FC, 407 FC) iz študije pri bolnikih v prvi liniji zdravljenja (preglednici 10a ter 10b) ter 552 bolnikov (276 R-FC, 276 FC) iz študije pri bolnikih, pri katerih se je bolezen ponovila oziroma so bili neodzivni na zdravljenje (preglednica 11).
Rituximab maintenance treatment reduced the risk of death by 56% (95% CI; 22%-75%).
Vzdrževalno zdravljenje z rituksimabom je zmanjšalo tveganje za smrt za 56 % (95-% interval zaupanja: 22-75 %).
If a patient develops PML, the dosing of rituximab must be permanently discontinued.
Če se pri bolniku razvije PML, je treba uporabo zdravila rituksimab dokončno ukiniti.
The final efficacy analysis included all randomised patients (197 CHOP, 202 R-CHOP), and had a median follow-up duration of approximately 31 months.
Končna analiza učinkovitosti je vključevala vse randomizirane bolnike (197 CHOP, 202 R-CHOP),
If you are having Ritemvia with other medicines, some of the side effects you may get may be due to the other medicines.
Če prejemate zdravilo Ritemvia skupaj z drugimi zdravili, se nekateri neželeni učinki lahko pojavijo zaradi drugih zdravil.
The two adverse events that were reported were flu-like symptoms, with a dose of 1.8 g of rituximab and fatal respiratory failure, with a dose of 2 g of rituximab.
Dva opisana neželena dogodka sta bila gripi podobni simptomi (pri odmerku 1,8 g rituksimaba) in odpoved dihal s smrtnim izidom (pri odmerku 2 g rituksimaba).
• The need to monitor patients for infections, especially PML, during and after Ritemvia treatment
• informacije o nujnosti, da bolnike spremljajo zaradi nastanka mogočih okužb, posebno progresivne multifokalne levkoencefalopatije (PML), med zdravljenjem z zdravilom Ritemvia in po njem,
The analysis of overall survival showed a significant benefit of R-FC treatment over FC chemotherapy alone (p=0.0319, log-rank test) (Table 10a).
Analiza celokupnega preživetja je pokazala signifikantno korist zdravljenja R-FC glede na samo kemoterapijo FC (p=0,0319, test log rank) (preglednica 10a).
Data from extended follow-up of patients in the study (median follow-up 9 years) confirmed the long-term benefit of rituximab maintenance therapy in terms of PFS, EFS, TNLT and TNCT (Table
Podatki iz podaljšanega spremljanja bolnikov v študiji (mediana spremljanja 9 let) so potrdili dolgoročno korist vzdrževalnega zdravljenja z zdravilom rituksimab glede na PFS, EFS, TNLT in TNCT (preglednica
18-months p = 0.016
18 mesecev p = 0,016
Disease activity outcomes
Vpliv na aktivnost bolezni
late neutropenia3
pozna nevtropenija3
Patients with a history of a serious infusion reaction to a biologic therapy for RA were excluded from entry.
Bolniki, ki so imeli v anamnezi resno reakcijo, povezano z infuzijo, na biološko zdravilo za zdravljenje revmatoidnega artritisa, v študijo niso bili vključeni.
Occurred at various times up to several months after completion of rituximab therapy
Pojavili so se različno, tudi do nekaj mesecev po končanem zdravljenju z rituksimabom.
NR: not reached; a: only applicable to patients achieving a CR
NR: ni doseženo; a: velja le za bolnike, ki so dosegli CR (popolni odgovor)
Nearly all infusion-related reactions were mild to moderate.
Skoraj vse z infundiranjem povezane reakcije so bile blage do zmerne.
Rarely fatal cases reported 5 signs and symptoms of cranial neuropathy.
5 Znaki in simptomi kranialne nevropatije.
A total of 117 patients (88 with GPA, 24 with MPA, and 5 with renal-limited ANCA-associated vasculitis) in disease remission were randomised to receive azathioprine (59 patients) or rituximab (58 patients) in a prospective, multi-center, controlled, open-label study.
Skupno 117 bolnikov (88 z GPA, 24 z MPA in 5 z ledvično omejenim z ANCA povezanim vaskulitisom), ki so bili v remisiji bolezni, so v prospektivni, multicentrični, kontrolirani odprti študiji randomizirali na prejemanje azatioprina (59 bolnikov) ali rituksimab (58 bolnikov).
Reactivation of hepatitis B infection has also been very rarely reported in rheumatoid arthritis patients receiving rituximab (see section 4.4).
reaktivaciji okužbe z virusom hepatitisa B so zelo redko poročali tudi pri bolnikih z revmatoidnim artritisom, ki so prejemali rituksimab (glejte poglavje 4.4).
• heart problems - such as reduced heart rate or chest pain (angina)
težave s srcem - na primer upočasnjen srčni utrip ali bolečina v prsih (angina pektoris),
In Trial 1, conducted in patients with inadequate response or intolerance to one or more TNF inhibitor therapies, receiving rituximab in combination with methotrexate demonstrated significantly less radiographic progression than patients originally receiving methotrexate alone at 56 weeks.
V preskušanju 1 je bilo pri bolnikih, ki so nezadovoljivo odgovorili na eno ali več zdravljenj z zaviralci TNF ali jih niso prenašali, in ki so prejemali rituksimab in metotreksat, po 56 tednih na posnetkih značilno manj znakov napredovanja kot pri tistih, ki so prvotno dobivali samo metotreksat.
The benefit in terms of PFS was observed in almost all patient subgroups analysed according to disease risk at baseline.
Korist v smislu preživetja brez napredovanja bolezni so opažali pri skoraj vseh podskupinah, ki so jih analizirali glede na tveganje bolezni pred vključitvijo.
All of these arrhythmias either occurred in the context of a rituximab infusion or were associated with predisposing conditions such as fever, infection, acute myocardial infarction or pre-existing respiratory and cardiovascular disease.
Vse motnje srčnega ritma so se pojavile v povezavi z infuzijo rituksimaba ali pa so bile povezane s predispozicijskimi stanji, kot so zvišana telesna temperatura, okužba, akutni miokardni infarkt ali predhodna respiratorna ali kardiovaskularna bolezen.
Initial treatment, weekly for 8 doses
Začetno zdravljenje, 8 odmerkov, enkrat na teden
Data from extended follow-up of patients in the study (median follow-up 9 years) confirmed the longterm benefit of rituximab maintenance therapy in terms of PFS, EFS, TNLT and TNCT (Table 7).
Podatki iz podaljšanega spremljanja bolnikov v študiji (mediana spremljanja 9 let) so potrdili dolgoročno korist vzdrževalnega zdravljenja z zdravilom rituksimab glede na PFS, EFS, TNLT in TNCT (preglednica 7).
Additional reactions reported in some cases were myocardial infarction, atrial fibrillation, pulmonary oedema and acute reversible thrombocytopenia.
Dodatne reakcije, o katerih so poročali v nekaterih primerih, so miokardni infarkt, atrijska fibrilacija, pljučni edem in akutna reverzibilna trombocitopenija.
The benefit in terms of PFS was consistently observed in most patient subgroups analysed according to disease risk at baseline (i.e. Binet stages A-C) (Table 10b).
Korist v smislu preživetja brez napredovanja bolezni so konsistentno opažali pri večini podskupin, ki so jih analizirali glede na tveganje bolezni pred vključitvijo (npr. stopnjo po Binetu A-C) (preglednica 10b).
• you have ever had or might now have a hepatitis infection.
• če ste kdaj imeli okužbo z virusom hepatitisa, ali če menite, da jo imate zdaj.
In the overall experience of rituximab repeat treatment over one year in rheumatoid arthritis, the proportions of patients with positive antibody titres against S. pneumoniae, influenza, mumps, rubella, varicella and tetanus toxoid were generally similar to the proportions at baseline.
Pri ponovnem enoletnem zdravljenju z rituksimabom pri revmatoidnem artritisu so bili deleži bolnikov s pozitivnim titrom protiteles proti S. pneumoniae, influenci, mumpsu, rdečkah, noricah in tetanusnem toksoidu na splošno podobni kot izhodiščni.
Following induction of remission with other standard of care immunosuppressants, Ritemvia maintenance treatment should be initiated during the 4 week period that follows disease remission.
Po indukciji remisije z drugimi imunosupresivi, ki spadajo v okvir običajnega zdravljenja, je treba vzdrževalno zdravljenje z zdravilom Ritemvia začeti v 4-tedenskem obdobju po remisiji bolezni.
• low numbers of platelets in the blood
nizko število trombocitov v krvi,
Based on the population pharmacokinetic analysis of data in 97 patients with granulomatosis with polyangiitis and microscopic polyangiitis who received 375 mg/m2 rituximab once weekly for four doses, the estimated median terminal elimination half-life was 23 days (range, 9 to 49 days).
Na podlagi populacijske farmakokinetične analize podatkov 97 bolnikov z granulomatozo s poliangiitisom in z mikroskopskim poliangiitisom, ki so štiri tedne prejemali 375 mg/m2 rituksimaba enkrat na teden, je ocenjeni mediani končni razpolovni čas izločanja 23 dni (razpon: od 9 do 49 dni).
• The need to provide patients with the Patient Alert Card with each infusion
• informacije o nujnosti, da opozorilno kartico izročijo bolniku ob vsakem infundiranju.
At this time, the infusion can be initially resumed at not more than one-half the previous rate.
Hitrost infuzije naj na začetku ne bo večja od polovice predhodne.
Concentrate for solution for infusion 500 mg / 50 mL
koncentrat za raztopino za infundiranje 500 mg/50 ml
• The need to carry the card at all times and to show the card to all treating health care professionals
• informacije o nujnosti, da jo imajo bolniki s sabo ves čas in da jo pokažejo vsem zdravnikom, ki jih zdravijo,
A higher proportion of patients receiving the original rituximab/MTX treatment also had no erosive progression over 56 weeks (Table 13).
Prav tako pri večjem deležu bolnikov, ki so prvotno prejemali rituksimab in metotreksat, ni prišlo do napredovanja erozij v 56 tednih (preglednica 13).
During the treatment course in studies with rituximab in combination with chemotherapy, grade 3/4 leucopenia (R-CHOP 88% vs. CHOP 79%, R-FC 23% vs. FC 12%), neutropenia (R-CVP 24% vs. CVP 14%; R-CHOP 97% vs. CHOP 88%, R-FC 30% vs. FC 19% in previously untreated CLL), pancytopenia (R-FC 3% vs. FC 1% in previously untreated CLL) were usually reported with higher frequencies when compared to chemotherapy alone.
Med zdravljenjem v študijah rituksimaba v kombinaciji s kemoterapijo sta bili 3. ali 4. stopnja levkopenije (R-CHOP 88% v primerjavi s CHOP 79%, R-FC 23% v primerjavi s FC 12%), nevtropenije (R-CVP 24% v primerjavi s CVP 14%, R-CHOP 97% v primerjavi s CHOP 88%, R-FC: 30% v primerjavi s FC 19% pri predhodno nezdravljeni KLL), pancitopenije (R-FC: 3% v primerjavi s FC 1% pri predhodno nezdravljeni KLL) po navadi pogostejši kot s kemoterapijo samo.
In patients with non-Hodgkin's lymphoma receiving rituximab in combination with cytotoxic chemotherapy, cases of hepatitis B reactivation have been reported (see non-Hodgkin's lymphoma).
Pri bolnikih z ne-Hodgkinovim limfomom, ki so prejemali rituksimab v kombinaciji s citotoksično kemoterapijo, so poročali o primerih reaktivacije virusa hepatitisa B (glejte ne-Hodgkinov limfom).